Skip to main content
DiagnosTear Technologies Inc. logo

DiagnosTear Technologies Inc. — Investor Relations & Filings

Ticker · DTR ISIN · CA25244H1055 LEI · 529900Y0T83PGBNF6A04 CSE Manufacturing
Open in API
Filings indexed 73 across all filing types
Latest filing 2025-08-27 Regulatory Filings
Country CA Canada
Listing CSE DTR

About DiagnosTear Technologies Inc.

https://diagnostear.com/

DiagnosTear Technologies Inc. is an ophthalmic company specializing in advanced, disruptive diagnostic solutions for the management of eye diseases. The company focuses on point-of-care diagnosis of front-of-the-eye pathologies through the analysis of tear fluid composition. Its primary technology platform, TeaRx, facilitates the multi-parameter assessment of conditions such as Dry Eye Syndrome (DES) and Severe Meibomian Gland Dysfunction (MGD). Products like the TeaRx Red Eye diagnostic device are designed for commercial readiness and large-scale manufacturing. TeaRx is positioned as a critical tool for pre- and post-operative assessment in cataract and refractive surgeries, aligning with current ophthalmic guidelines.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 0% confidence The document is a Form 52-109FV2 certification by the CEO relating to interim financial filings for the period ended June 30, 2025. It is not the interim financial report or MD&A itself but a regulatory compliance certificate required under Canadian NI 52-109. It does not announce publication of a report (so not RPA) and does not contain substantive financials or management discussion beyond the certificate language. This best fits the general “Regulatory Filings” catch-all category.
2025-08-27 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is Form 52-109FV2, a Venture Issuer Basic Certificate under NI 52-109, where the CFO certifies the interim financial report and MD&A for the period ended June 30, 2025. It is a compliance certification rather than the interim report itself. There is no specific category for officer certificates under NI 52-109, so this falls under general regulatory filings (RNS) as a fallback.
2025-08-27 English
Interim MD&A - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a press release announcing the mailing of the company’s management information circular (proxy statement) for its upcoming annual and special meeting, and it details soliciting shareholder approval for a new stock option plan. This fits the definition of Proxy Solicitation & Information Statement (Code: PSI).
2025-05-26 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate” whereby the CFO certifies the interim financial report and interim MD&A for the quarter ended March 31, 2025 under NI 52-109. It is not the interim report itself (IR) but a regulatory certification filing. No other category specifically covers certification forms, so it falls into the fallback “Regulatory Filings” (RNS).
2025-05-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 Certification of Interim Filings under Canadian NI 52-109, where the CEO certifies the interim financial report and interim MD&A. It is not the interim report itself nor an announcement of its publication, but a statutory attestation form accompanying regulatory filings. There is no specific category for certification forms in our taxonomy, so it falls under the general Regulatory Filings (RNS) fallback.
2025-05-26 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a regulatory form (Form 13-502F1) submitted to the Ontario Securities Commission, detailing participation fees under OSC Rule 13-502 Fees, including market values, certification, and fee calculation. It is not a financial report (annual, quarterly, earnings, etc.) nor a notice of dividend, delisting, M&A, or director transaction. It is a miscellaneous regulatory filing, best classified under ‘Regulatory Filings’ (RNS).
2025-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.